Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial

Autor: Ana-María Lacosta, María Pascual-Lucas, Pedro Pesini, Diego Casabona, Virginia Pérez-Grijalba, Iván Marcos-Campos, Leticia Sarasa, Jesus Canudas, Hassnae Badi, Inmaculada Monleón, Itziar San-José, Josep Munuera, Octavio Rodríguez-Gómez, Carla Abdelnour, Asunción Lafuente, Mar Buendía, Mercè Boada, Lluis Tárraga, Agustín Ruiz, Manuel Sarasa

Publikováno v: Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-13 (2018)

Abstract Background Immunotherapy targeting the amyloid-β (Aβ) peptide is a promising strategy for the treatment of Alzheimer’s disease (AD); however, none of the active or passive vaccines tested have been demonstrated to be effective to date. W

Externí odkaz: https://doaj.org/article/1030c599a5ae4b4d8f002a265d9af497

Blood amyloid beta levels in healthy, mild cognitive impairment and Alzheimer's disease individuals: replication of diastolic blood pressure correlations and analysis of critical covariates.

Autor: Agustín Ruiz, Pedro Pesini, Ana Espinosa, Virginia Pérez-Grijalba, Sergi Valero, Oscar Sotolongo-Grau, Montserrat Alegret, Inmaculada Monleón, Asunción Lafuente, Mar Buendía, Marta Ibarria, Susana Ruiz, Isabel Hernández, Itziar San José, Lluís Tárraga, Mercè Boada, Manuel Sarasa

Publikováno v: PLoS ONE, Vol 8, Iss 11, p e81334 (2013)

Plasma amyloid beta (Aβ) levels are being investigated as potential biomarkers for Alzheimer's disease. In AB128 cross-sectional study, a number of medical relevant correlates of blood Aβ40 or Aβ42 were analyzed in 140 subjects (51 Alzheimer's dis

Externí odkaz: https://doaj.org/article/1144d95a6c12445f803e453f2c87a54d

Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study

Autor: Manuel Sarasa, Mar Buendía, Pablo Martinez-Lage, Mercè Boada, Oscar Sotolongo-Grau, Judith Romero, Inmaculada Monleón, Josep Munuera, Montserrat Alegret, Javier Arbizu, Isabel Hernández, Elena Prieto, Lluís Tárraga, Agustín Ruiz, Virginia Pérez-Grijalba, Fernando Guillen, Pedro Pesini, Itziar San-José, Leticia Sarasa

Publikováno v: Alzheimer’s Research & Therapy, Vol 11, Iss 1, Pp 1-9 (2019)
Dadun. Depósito Académico Digital de la Universidad de Navarra
Consejo Superior de Investigaciones Científicas (CSIC)
Alzheimer's Research & Therapy
ALZHEIMERS RESEARCH & THERAPY
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu

BackgroundTo facilitate population screening and clinical trials of disease-modifying therapies for Alzheimer’s disease, supportive biomarker information is necessary. This study was aimed to investigate the association of plasma amyloid-beta (Aβ)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48579370ed8e0d9131471b3ddaa53fbe
https://doaj.org/article/8ea557f727a645db9b4c9c8e9f242844

Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial

Autor: Mar Buendía, Leticia Sarasa, Octavio Rodriguez-Gomez, Inmaculada Monleón, Carla Abdelnour, Virginia Pérez-Grijalba, Josep Munuera, María Pascual-Lucas, Hassnae Badi, Mercè Boada, Iván Marcos-Campos, Ana-María Lacosta, Pedro Pesini, Diego Casabona, Lluís Tárraga, Asunción Lafuente, Itziar San-José, Manuel Sarasa, Jesús Canudas, Agustín Ruiz

Publikováno v: Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-13 (2018)

Background Immunotherapy targeting the amyloid-β (Aβ) peptide is a promising strategy for the treatment of Alzheimer’s disease (AD); however, none of the active or passive vaccines tested have been demonstrated to be effective to date. We have de

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43050109efbefedc7191fcc3217fd290
http://link.springer.com/article/10.1186/s13195-018-0340-8

Cytotoxicity of quinone drugs on highly proliferative human leukemia T cells: Reactive oxygen species generation and inactive shortened SOD1 isoform implications

Autor: María A. Alava, María Iturralde, Pedro Iñarrea, Julián Pardo, Inmaculada Monleón, Juan Ignacio Aguilo, Alberto Anel, María José Martínez-Lorenzo

Publikováno v: Chemico-Biological Interactions. 198:18-28

Drugs containing the quinone group were tested on hyperproliferative leukemia T cells (HLTC: Jhp and Jws) and parental Jurkat cells. Doxorubicin, menadione and adaphostin produced different effects on these cell lines. Rapid doxorubicin-induced cell

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::141f72f24fd07f9a59af776b72fdd40c
https://doi.org/10.1016/j.cbi.2012.05.001